Optimizing Site Selection for Phase III Oncology Trials Using Data-Driven Insights

Objective:

A pharmaceutical company is planning to launch a Phase III clinical trial for a new oncology drug. They aim to recruit patients efficiently and effectively across diverse geographic regions, while ensuring the selected sites are well-suited for the trial.

[Step 1] Evaluate Patient Populations

Start by doing a deep dive on patients to understand more about who they are. Utilize details of patient demographics, including geography (Zip 3), social determinants of health (SDOH) attributes and more. At this step additional analysis can be done to expand or narrow down the criteria.

Patient Demographics

SDOH

Geography

[Step 2] Investigator/HCP Profiling Details

Digging into the investigator/HCP level detail provides information on their practice, affiliations, referral network, claim volumetrics, external influences, clinical trial experience and more. SDOH data is integrated at the patient, provider, and practice level.

Clinical Trial Information Card

Clinical Trial Dashboard

[Step 3] Finalize Investigator/HCP List for Extract

Upon final selection, target lists can be extracted and downloaded for implementation and activation.

[Result]

This pharmaceutical company was able to optimize the site selection process for their Phase III oncology trial by utilizing claims data. They identified high-performing sites with experienced investigators and a strong track record of patient recruitment. By using a data-driven approach it enabled them to efficiently recruit a diverse and representative patient population.

By leveraging PurpleLab’s advanced analytics and data-driven insights, pharmaceutical companies can optimize site selection, accelerate patient recruitment, and ultimately improve the efficiency and success of their clinical trial.

Need More Information?

Questions? Ready for a demo or free trial of our HealthNexus™ platform? Contact us to get started.